| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ARMD7; CARASIL; High-temperature requirement A serine peptidase 1; HtrA; HtrA serine peptidase 1; HTRA1; IGFBP5 protease; ORF480; Protease serine 11 (IGF binding); protease serine 11; PRSS11; Serine protease 11; Serine protease HTRA1;;Serine protease HTRA1 |
| WB Predicted band size | 51 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | A synthesized peptide derived from human Serine protease HTRA1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.05% BSA and 50% glycerol. |
+ +
以下是关于HTRA1抗体的3篇参考文献示例(内容为虚构，仅供格式参考)：
1. **文献名称**: "HTRA1 Expression in Age-Related Macular Degeneration: A Histochemical Study"
**作者**: Grau S, et al.
**摘要**: 本研究通过免疫组化分析HTRA1在AMD患者视网膜中的表达，发现HTRA1蛋白水平显著升高，其抗体特异性验证为降解细胞外基质的关键作用提供依据，提示HTRA1可能成为治疗靶点。
2. **文献名称**: "HTRA1 as a Prognostic Biomarker in Epithelial Ovarian Cancer"
**作者**: De Luca A, et al.
**摘要**: 利用HTRA1特异性抗体对卵巢癌组织进行检测，发现高表达HTRA1与患者不良预后相关，机制涉及增强癌细胞侵袭性，支持HTRA1抗体在临床诊断中的应用潜力。
3. **文献名称**: "Neutralizing HTRA1 Antibody Attenuates Fibrosis in Rheumatoid Arthritis Synovium"
**作者**: Tsuchiya A, et al.
**摘要**: 研究开发了一种中和性HTRA1单克隆抗体，体外实验显示其有效抑制滑膜成纤维细胞的异常活化，动物模型中显著减轻关节炎症，为类风湿性关节炎治疗提供新策略。
注：以上文献及摘要均为模拟示例，实际研究需查询真实数据库(如PubMed)。
The HtrA1 (high-temperature requirement A1) antibody targets a secreted serine protease belonging to the HtrA family, which plays critical roles in extracellular matrix (ECM) remodeling, cell signaling, and stress response. HtrA1. encoded by the *HTRA1* gene, consists of an IGF-binding domain, a Kazal-type protease inhibitor domain, and a PDZ domain, enabling its interaction with substrates like TGF-β, fibronectin, and amyloid-β. Dysregulation of HtrA1 is linked to pathologies including age-related macular degeneration (AMD), osteoarthritis, cancer, and preeclampsia. In AMD, HtrA1 overexpression contributes to choroidal neovascularization by degrading ECM components, while in cancer, it exhibits dual roles—acting as a tumor suppressor or promoter depending on context.
HtrA1 antibodies are tools for detecting protein expression in tissues or fluids and modulating its enzymatic activity. Neutralizing antibodies inhibit HtrA1 proteolytic function, offering therapeutic potential in diseases driven by excessive ECM degradation. Conversely, diagnostic assays using HtrA1 antibodies help quantify protein levels in conditions like preeclampsia, where placental HtrA1 overexpression correlates with disease severity. Research also explores HtrA1 antibodies in biomarker discovery and understanding molecular pathways in neurodegeneration. Their development remains pivotal for both mechanistic studies and clinical applications targeting HtrA1-associated disorders.
×
